Bris­tol My­ers cuts mid-stage NASH, an­ti-TIG­IT pro­grams

Bris­tol My­ers Squibb dis­closed Thurs­day at its R&D Day that it cut six pro­grams, in­clud­ing mid-stage drug can­di­dates for NASH and sol­id tu­mors.

The New Jer­sey phar­ma com­pa­ny axed an siR­NA for NASH, known as HSP47, which it li­censed from Nit­to Denko for $100 mil­lion up­front in 2016. Bris­tol My­ers com­plet­ed a Phase II study in 2019 in­ves­ti­gat­ing the ther­a­py in pa­tients with ad­vanced liv­er fi­bro­sis, or scar tis­sue buildup, af­ter they were cured of he­pati­tis C. It had test­ed two dif­fer­ent dos­es ver­sus place­bo in 61 pa­tients, but both dos­es failed to make a dif­fer­ence in liv­er scar­ring com­pared to place­bo, ac­cord­ing to re­sults in the fed­er­al clin­i­cal tri­als data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER